Skip to main content
InSilico Medicine Cayman TopCo logo

InSilico Medicine Cayman TopCo — Investor Relations & Filings

Ticker · 3696 ISIN · KYG4790P1037 LEI · 254900MQK3C1TR58H275 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 49 across all filing types
Latest filing 2026-05-27 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 3696

About InSilico Medicine Cayman TopCo

https://insilico.com

InSilico Medicine Cayman TopCo is a biotechnology company focused on transforming drug discovery and development using proprietary generative artificial intelligence (AI) and automation. The company operates an end-to-end AI-driven pipeline, leveraging its Pharma.ai platform, which incorporates tools such as PandaOmics and Large Language of Life Models (LLLMs), to rapidly identify novel therapeutic targets and generate new molecular structures. Its core mission is to extend healthy longevity. InSilico Medicine develops therapeutic programs targeting a wide range of diseases, including various forms of cancer (e.g., BRCA-mutant, MTAP deficient), fibrosis, immunity, central nervous system disorders, and infectious diseases (e.g., COVID-19), advancing multiple candidates through preclinical and clinical stages.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT
Regulatory Filings Classification · 82% confidence The document is a short voluntary announcement on the Hong Kong Exchange platform regarding the company’s evaluation of a potential secondary listing. It does not contain any actual financial data, vote results, management changes, or proxy materials, nor is it a formal report (10-K, IR, AR, etc.). It is a general regulatory announcement/fallback category under the Rules Governing the Listing of Securities on HKEX. Therefore, it best fits “Regulatory Filings” (RNS).
2026-05-27 English
VOLUNTARY ANNOUNCEMENT INCLUSION AS A CONSTITUENT OF HANG SENG BIOTECH INDEX
Regulatory Filings Classification · 85% confidence The document is a voluntary announcement by the company about its inclusion as a constituent of the Hang Seng Biotech Index. It does not contain financial statements or constitute a formal report (10-K, interim report), nor does it relate to board changes, dividends, or other specific categories. This is a general regulatory announcement about a corporate event (index inclusion) and best fits the Regulatory Filings (RNS) fallback category.
2026-05-26 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return report for an equity issuer listed on the Hong Kong Stock Exchange, specifically under Chapter 19B of the Exchange Listing Rules. It includes detailed movements in authorised share capital, issued shares, treasury shares, share options, and confirmations related to compliance with listing rules and regulatory requirements. The document is not an announcement of a report but a regulatory filing with substantive data on share capital movements and confirmations. It does not fit into categories like Annual Report, Earnings Release, or Capital/Financing Update, but rather aligns with regulatory compliance and reporting requirements. Given the nature and format, this document best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2026-05-07 English
DISCLOSEABLE TRANSACTIONS SUBSCRIPTIONS OF WEALTH MANAGEMENT PRODUCTS
Regulatory Filings Classification · 88% confidence The document is a Hong Kong Stock Exchange announcement disclosing a related-party transaction (subscriptions of wealth management products) under the Listing Rules (Chapter 14). It is not a financial report (10-K, IR, ER), not a shareholder meeting material, and not a detailed management discussion—it is a regulatory announcement of a discloseable transaction. This fits the fallback category for miscellaneous regulatory filings (RNS).
2026-04-30 English
VOLUNTARY ANNOUNCEMENT INSILICO'S RENTOSERTIB INHALATION SOLUTION RECEIVES IND APPROVAL FROM CDE
Regulatory Filings Classification · 85% confidence The document is a voluntary announcement on a Hong Kong Exchange platform about Insilico’s IND approval for a pharmaceutical product. It contains no financial results, earnings metrics, or meeting materials but is a general regulatory/business update. It does not fit into categories such as earnings release, interim report, investor presentation, share issuance, or board changes. It is best classified as a general regulatory filing (RNS).
2026-04-29 English
Notification Letter to Non-registered Holders of and Request Form - Arrangement of Electronic Dissemination of Corporate Communications
Regulatory Filings Classification · 80% confidence The document is a shareholder letter regarding the arrangement for electronic dissemination of corporate communications under HKEX Listing Rule 2.07A. It is not a financial report (e.g., Annual or Interim Report), nor an AGM presentation, dividend notice, or a management change announcement. It does not attach or summarize a specific financial report; instead, it informs shareholders how future corporate communications will be made available. This is a general regulatory announcement and falls into the fallback category “Regulatory Filings (RNS).”
2026-04-28 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.